Our results provide compelling data to suggest that genetic testing should not be restricted to high-risk individuals, but rather should be offered to all people with Parkinson’s disease.3,6,7 For example, while as expected, GBA1 and LRRK2 variants were more common among people of Ashkenazi Jewish ancestry compared with those without any high-risk ancestries, most who possessed these variants were non-Ashkenazi Jewish (Supplementary Table 4). Here, GBA1 is linked to Parkinson disease.